A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Apr 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new blood test called NavDx® to see if it can help detect oropharyngeal cancer (a type of throat cancer) that is linked to the Human Papillomavirus (HPV). The researchers believe that this test can find small pieces of DNA from HPV in the blood, which may indicate the presence of cancer early on. Early detection can be crucial for effective treatment, so the study aims to understand how well this blood test works for identifying HPV-related cancers.

To participate in this trial, you need to be at least 45 years old and have had four or more sexual partners in your lifetime, including one or more oral sexual partners. It's important to note that you should not have been diagnosed with HPV-related head and neck cancer before. If you join the study, you'll undergo the blood test, and the researchers will monitor the results to see how effectively it can identify cancer. This study is currently looking for participants, and anyone interested should consider whether they meet the eligibility criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ages 45 and older
• • Self-reported history of four or more lifetime sexual partners
• • Self-reported history of one or more lifetime oral sexual partner
• • No previous history of diagnosed HPV-related head and neck cancer
• Exclusion Criteria:
• • History of diagnosed HPV-related OPC
• • Less than three sexual partners in lifetime
• • No history of oral sex performed
• • Younger than age 45